IBI-20089 is IBI’s first product to enter clinical trials. It is the first injectable intraocular sustained release product for the delivery of triamcinolone acetonide. IBI-20089 is designed to deliver triamcinolone acetonide for up to one year with a single intravitreal injection, with the duration of delivery volume dependent.
IBI-20089 is administered as a standard intravitreal injection that eliminates the need for additional devices or surgical procedures. Formulated as a gel, IBI-20089 forms a sphere in the posterior segment after intravitreal injection. This sphere gradually degrades and disappears as the drug is released in a controlled manner.
IBI has completed a Phase 1/2 clinical trial of IBI-20089 in patients with cystoid macular edema associated with retinal vein occlusion. The clinical trial included two dosing levels, a 25-µl dose designed to last six months and a 50-µl dose designed to last one year. The results of the clinical trial confirm the expected safety and efficacy characteristics of the product, along with the controlled-release attributes of the Verisome® technology.
A “Proof of Concept” trial using IBI-20089 in conjunction with Lucentis® targeting “wet” AMD is nearing completion.
There are more than 20 ocular diseases that IBI-20089 may eventually treat.